Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells

Angiogenesis, the formation of new blood vessels, is an essential step for cancer progression, but antiangiogenic therapies have shown limited success. Therefore, a better understanding of the effects of antiangiogenic treatments on endothelial cells is necessary. In this study, we evaluate the changes in cell surface vascular endothelial growth factor receptor (VEGFR) expression on endothelial cells in culture treated with the antiangiogenic tyrosine kinase inhibitor drug sunitinib, using quantitative flow cytometry. We find that proangiogenic VEGFR2 cell surface receptor numbers are increased with sunitinib treatment. This proangiogenic effect might account for the limited effects of sunitinib as a cancer therapy. We also find that this increase is inhibited by brefeldin A, an inhibitor of protein transport from the endoplasmic reticulum to the Golgi apparatus. The complex dynamics of cell surface VEGFRs may be important for successful treatment of cancer with antiangiogenic therapeutics.

[1]  Aleksander S. Popel,et al.  Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies , 2011, BMC Systems Biology.

[2]  Stacey D. Finley,et al.  Compartment Model Predicts VEGF Secretion and Investigates the Effects of VEGF Trap in Tumor-Bearing Mice , 2013, Front. Oncol..

[3]  Stacey D. Finley,et al.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. , 2013, Journal of the National Cancer Institute.

[4]  Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment , 2013, Journal of Molecular Medicine.

[5]  A. Popel,et al.  Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. , 2011, Experimental cell research.

[6]  Y. Hida,et al.  Tumour endothelial cells acquire drug resistance in a tumour microenvironment. , 2013, Journal of biochemistry.

[7]  Y. Misumi,et al.  Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. , 1986, The Journal of biological chemistry.

[8]  A. Popel,et al.  Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts , 2014, Cancer medicine.

[9]  Stacey D. Finley,et al.  A Two-Compartment Model of VEGF Distribution in the Mouse , 2011, PloS one.

[10]  A. Popel,et al.  Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. , 2013, American journal of physiology. Heart and circulatory physiology.

[11]  L. Claesson‐Welsh,et al.  Signal transduction by vascular endothelial growth factor receptors. , 2011, The Biochemical journal.

[12]  A. Ryan,et al.  Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells , 2008, Clinical Cancer Research.

[13]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[14]  Aleksander S Popel,et al.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. , 2014, Cytokine & growth factor reviews.

[15]  K. Arima,et al.  Antiviral activity of brefeldin A and verrucarin A. , 1968, The Journal of antibiotics.

[16]  Nupura S. Bhise,et al.  Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis , 2011, Expert opinion on drug delivery.

[17]  R. Jain.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[19]  Robert S. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  L. Claesson‐Welsh,et al.  VEGFA and tumour angiogenesis , 2013, Journal of internal medicine.

[22]  J. Lippincott-Schwartz,et al.  Brefeldin A: insights into the control of membrane traffic and organelle structure , 1992, The Journal of cell biology.

[23]  J. Hochman,et al.  Cultured rat hepatocytes. , 1996, Pharmaceutical biotechnology.

[24]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[25]  Rakesh K Jain,et al.  Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? , 2013, Journal of the National Cancer Institute.

[26]  K. Thomas.  Vascular Endothelial Growth Factor Receptors , 2004 .

[27]  F. Peale,et al.  Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors , 2012, The Journal of pathology.

[28]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  Chien-Fu Huang,et al.  Brefeldin A Effectively Inhibits Cancer Stem Cell-Like Properties and MMP-9 Activity in Human Colorectal Cancer Colo 205 Cells , 2013, Molecules.

[30]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[31]  A. Larsen,et al.  Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. , 2011, Pharmacology & therapeutics.

[32]  Stacey D. Finley,et al.  Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms , 2012, The AAPS Journal.

[33]  M. Sekine,et al.  Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1 , 2007, PLoS medicine.

[34]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[35]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[36]  P. Carmeliet,et al.  Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. , 2011, Current opinion in genetics & development.

[37]  Gareth Howell,et al.  Intrinsic Tyrosine Kinase Activity is Required for Vascular Endothelial Growth Factor Receptor 2 Ubiquitination, Sorting and Degradation in Endothelial Cells , 2006, Traffic.

[38]  Sonja Loges,et al.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. , 2013, The Journal of clinical investigation.

[39]  S. Koch,et al.  Signal transduction by vascular endothelial growth factor receptors. , 2012, Cold Spring Harbor perspectives in medicine.

[40]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[41]  A. Popel,et al.  Expression of VEGF Receptors on Endothelial Cells in Mouse Skeletal Muscle , 2012, PloS one.

[42]  Helmut Friess,et al.  VEGF-RII Influences the Prognosis of Pancreatic Cancer , 2002, Annals of surgery.